Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, Excretion and Safety of [(14)C]ADC189 in Healthy Chinese Male Volunteers
NCT06360796Phase 1Completed
- Sponsor
- Jiaxing AnDiCon Biotech
- Start
- Nov 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deunoxavir marboxil in Influenza A (IAV) and influenza B, sponsored by Jiaxing AnDiCon Biotech. Primary endpoints: Area Under the Curve at 504 hours, Maximum Plasma Concentration at 504 hours and 2 more. Started Nov 2023; status: completed.
02
Drugs
deunoxavir marboxil
03
Conditions
Influenza A (IAV)influenza B
Beyond the preview
Go deeper on NCT06360796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360796.